Jonathan M. Shillingford PhD

Jonathan currently works at Endocyte, a biotech company that specializes in the development of small-molecule drug conjugates for the identification and treatment of people with cancer and other diseases, where he heads the Cell Biology group.
Prior to his current position, he was part of the scientific editorial team at Intervention Insights, a company in the Health Information Services sector that aligns molecular information with molecularly-targeted therapeutics in the field of oncology. His basic research experience, which spans 15+ years, includes the study of intracellular signaling pathways that contribute to polycystic kidney disease and signaling pathways involved in the basic biology of the mammary gland.